Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults
Vaccine effectiveness of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% (95% CI, 30-63) and 45% (95% CI, 35-54) against emergency department/urgent care encounters (vs no KP.2 vaccine at <3 months). Protection persisted >90 days from vaccination with some waning. Vaccine effectiveness remained high regardless of prior COVID-19 vaccination and among older adults.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Timothy B. Frankland (ORCID: https://orcid.org/0000-0002-0987-8405)
- Sara Y. Tartof (ORCID: https://orcid.org/0000-0003-2336-8476)
- J.M. Slezak
- Laura Puzniak
Institutions
- Hawaii Department of Health (US)
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Hawaii Permanente Medical Group (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1093/ofid/ofag019
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 32.78